Flexible Launch Support That helps you scale!
From targeted strategic sprints to comprehensive launch orchestration, we provide the specialized expertise your advanced therapy launch demands.
Expertise Overview
At Mireso Consulting, we bring 20+ years of specialized expertise in cell & gene therapy and rare disease commercialization. Our knowledge isn't theoretical, it's built on 10+ successful launches, including the Yescarta CAR-T launch that exceeded all KPIs.
We understand the unique complexities you face: intense payer scrutiny, high-cost therapy reimbursement, rare patient identification, and cross-functional orchestration. Having managed $250M+ portfolios across oncology, hematology, CNS, and ultra-rare diseases, we combine scientific credibility with commercial acumen.
Whether you're preparing for your first launch or scaling your portfolio, we deliver specialized knowledge and hands-on execution that turns breakthrough science into commercial success.
BOOK YOUR APPOINTMENT
To cut down on your waiting time, simply book your appointment online.
EXPERTISE PACKAGES
Project-Based Strategy
Perfect for early-stage biotech preparing for first-in-human or pivotal trials, or larger firms needing a sprint team for critical gaps in your launch planning.
What's included:
- Focused strategic consulting (4-8 weeks)
- Specific deliverable (market access strategy, launch readiness assessment, or competitive positioning)
- Expert analysis and actionable recommendations
- Executive presentation and handoff
Modular Launch PMO
If you have late-stage assets and lean teams, this is the package for you. Comprehensive support across market access, medical affairs, commercial, and patient engagement—modular and flexible.
What's Included:
- End-to-end launch orchestration (6-18 months)
- Cross-functional PMO governance
- Market access, medical affairs, commercial, and patient engagement modules
- Ongoing strategic guidance and execution support
- Performance tracking and optimization
- Fractional leadership access
Fractional Leadership
Our most comprehensive package, perfect for mid-sized biopharma scaling a CGT or rare disease portfolio with strong R&D but limited commercial bench strength.
What's Included:
- Embedded fractional Chief Commercial Officer or VP-level support
- Strategic planning and execution oversight
- Board-level reporting and investor relations support
- Team development and capability building
- Advisory board participation
- Full access to Mireso's network and expertise
- Ongoing optimization through launch and beyond
Every launch is unique
We recognize that every advanced therapy launch presents distinct challenges and opportunities. If our standard service models don't perfectly align with your needs, we create fully tailored engagement models designed specifically for your asset, organization, stage, and strategic objectives.